According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
Themis will market this drug with the brand name REMITHEM.
USFDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma Limited manufacturing facility located at Lexington (Kentucky, USA) and the inspection has now been successfully closed by the USFDA
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities
Subscribe To Our Newsletter & Stay Updated
